| __timestamp | Bio-Techne Corporation | ImmunityBio, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 4326000 |
| Thursday, January 1, 2015 | 119401000 | 226206000 |
| Friday, January 1, 2016 | 140879000 | 94391000 |
| Sunday, January 1, 2017 | 199243000 | 53821000 |
| Monday, January 1, 2018 | 240636000 | 35463000 |
| Tuesday, January 1, 2019 | 264359000 | 46456000 |
| Wednesday, January 1, 2020 | 260583000 | 71318000 |
| Friday, January 1, 2021 | 324951000 | 135256000 |
| Saturday, January 1, 2022 | 372766000 | 102708000 |
| Sunday, January 1, 2023 | 378378000 | 129620000 |
| Monday, January 1, 2024 | 396826000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Bio-Techne Corporation and ImmunityBio, Inc. have taken different paths in this regard over the past decade. From 2014 to 2023, Bio-Techne's SG&A expenses have shown a steady increase, peaking at approximately 396 million in 2023, reflecting a growth of over 550% from 2014. In contrast, ImmunityBio's expenses have fluctuated, with a notable peak in 2015, where costs surged to 226 million, before stabilizing around 130 million in recent years. This suggests that while Bio-Techne has consistently expanded its operational scale, ImmunityBio has experienced more volatility, possibly due to strategic shifts or market challenges. Understanding these trends provides valuable insights into each company's operational strategies and financial priorities.
Novartis AG or Bio-Techne Corporation: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Bio-Techne Corporation vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Bausch Health Companies Inc.
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Evotec SE
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and ImmunityBio, Inc.
Comparing SG&A Expenses: Catalent, Inc. vs ImmunityBio, Inc. Trends and Insights
Comparing SG&A Expenses: ImmunityBio, Inc. vs MannKind Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and Taro Pharmaceutical Industries Ltd.